Literature DB >> 20464476

Lack of an association between AURKA T91A polymorphisms and breast cancer: a meta-analysis involving 32,141 subjects.

Haiming Sun1, Jing Bai, Feng Chen, Yan Jin, Yang Yu, Songbin Fu.   

Abstract

Several studies have investigated the associations between AURKA T91A polymorphism and the susceptibility to breast cancer, but the results have been inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. A total of 11 case-control studies, including 14,361 cases and 17,780 controls, were selected. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association in the additive model, dominant model, and recessive model. When all the studies were pooled into the meta-analysis, there was no evidence showing a significant association between AURKA T91A polymorphism and breast cancer risk (for additive model, OR = 0.839, 95% CI = 0.678-1.038; for dominant model: OR = 0.890, 95% CI = 0.757-1.074; and for recessive model: OR = 0.987, 95% CI = 0.963-1.012). In the subgroup analysis by ethnicity, significantly decreased risks were found for Asians (additive model, OR = 0.857, 95% CI = 0.742-0.991). When stratified by study design, no significant association was found between the polymorphism and breast cancer risk. In conclusion, this meta-analysis indicates that the AURKA T91A polymorphism is not a risk factor for developing breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20464476     DOI: 10.1007/s10549-010-0936-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

Review 1.  Germline Variants Impact Somatic Events during Tumorigenesis.

Authors:  Johnny R Ramroop; Madelyn M Gerber; Amanda Ewart Toland
Journal:  Trends Genet       Date:  2019-05-22       Impact factor: 11.639

2.  Genetic variation in cell cycle regulatory gene AURKA and association with intrinsic breast cancer subtype.

Authors:  Nicholas J Taylor; Jeannette T Bensen; Charles Poole; Melissa A Troester; Marilie D Gammon; Jingchun Luo; Robert C Millikan; Andrew F Olshan
Journal:  Mol Carcinog       Date:  2014-10-18       Impact factor: 4.784

Review 3.  Ethnic background and genetic variation in the evaluation of cancer risk: a systematic review.

Authors:  Lijun Jing; Li Su; Brian Z Ring
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

4.  The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism.

Authors:  Anja Pickhard; Michael Siegl; Alexander Baumann; Maximilian Huhn; Markus Wirth; Rudolf Reiter; Martina Rudelius; Guido Piontek; Gero Brockhoff
Journal:  Oncotarget       Date:  2014-07-30

5.  The Aurora-Kinase A Phe31-Ile polymorphism as possible predictor of response to treatment in head and neck squamous cell carcinoma.

Authors:  Anna Maria S Buchberger; Alexander Baumann; Guido Piontek; Dominik Schüttler; Martina Rudelius; Rudolf Reiter; Lena Gebel; Gerhard Piendl; Gero Brockhoff; Anja Pickhard
Journal:  Oncotarget       Date:  2018-01-30

6.  Association between the functional polymorphism Ile31Phe in the AURKA gene and susceptibility of hepatocellular carcinoma in chronic hepatitis B virus carriers.

Authors:  Zhiyu Bao; Lei Lu; Xinyi Liu; Bingqian Guo; Yun Zhai; Yuanfeng Li; Yahui Wang; Bobo Xie; Qian Ren; Pengbo Cao; Yuqing Han; Weihua Jia; Minshan Chen; Xinqiang Liang; Xuan Wang; Yi-Xin Zeng; Fuchu He; Hongxing Zhang; Ying Cui; Gangqiao Zhou
Journal:  Oncotarget       Date:  2017-06-27

7.  AURKA rs2273535 T>A Polymorphism Associated With Cancer Risk: A Systematic Review With Meta-Analysis.

Authors:  Shujie Wang; Jian Qi; Meiling Zhu; Meng Wang; Jinfu Nie
Journal:  Front Oncol       Date:  2020-06-30       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.